Helus Pharma Completes Phase 3 Enrollment for HLP003 in MDD, Eyes Q4 Data
Event summary
- Helus Pharma appointed Michael Halstead, former President of Intra-Cellular Therapies, as CEO.
- Completed enrollment in Phase 3 APPROACH study for HLP003 in Major Depressive Disorder (MDD), with topline data expected Q4 2026.
- Raised $50 million in June 2026 to support clinical development programs.
- HLP004 Phase 2 data showed clinically meaningful improvement in generalized anxiety disorder (GAD).
- Cash position stood at $166.4 million as of June 30, 2026.
The big picture
Helus Pharma is advancing its serotonergic agonist pipeline with key clinical milestones, positioning itself in the competitive mental health treatment space. The completion of Phase 3 enrollment for HLP003 and strong Phase 2 data for HLP004 highlight the company's focus on addressing unmet needs in depression and anxiety. With a robust cash position and strategic leadership changes, Helus Pharma aims to execute its clinical and commercial strategy effectively.
What we're watching
- Clinical Milestones
- Whether Helus Pharma can deliver topline data for HLP003 on schedule in Q4 2026.
- Regulatory Pathway
- How the FDA's Breakthrough Therapy Designation will influence HLP003's approval process.
- Pipeline Progression
- The pace at which Helus Pharma advances HLP004 and HLP005 through development stages.
Related topics